Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-RM2 PET/CT for Prostate Cancer Staging
NCT03113617Phase 2Completed
- Sponsor
- Andrei Iagaru
- Start
- Apr 2017
- Primary completion
- Dec 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 68Ga-DOTA-Bombesin in prostate cancer (PCa), sponsored by Andrei Iagaru. Primary endpoint: Sensitivity, Specificity, Positive, and Negative Predictive Value of 68Ga-RM2 PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy at 1 week. Started Apr 2017; status: completed.
02
Drugs
68Ga-DOTA-Bombesin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03113617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03113617.